We aimed to estimate hepatitis B surface antigen (HBsAg) positivity among birth year-stratified pregnant women in Hiroshima, Japan, and compare prevalence rates between women born before and after implementation of a national immunoprophylactic vaccination program for babies born to hepatitis B virus (HBV) carrier mothers in Japan.
INTRODUCTION
W ORLDWIDE, AN ESTIMATED 2 billion people are infected with the hepatitis B virus (HBV), and an additional 240 million are considered chronic HBV carriers (i.e., remain in a persistent HBV carrier state).
1 Between 0.6 and 1 million deaths are attributed to HBV-related liver diseases (e.g., chronic active hepatitis, cirrhosis, and liver cancer) each year. High prevalence rates of HBV surface antigen (HBsAg) positivity (>8%), a marker of chronic HBV infection, have been observed in the pan-Pacific zone (except for Japan, Australia, and New Zealand), Southeast Asia, Middle East/Central Asia, and parts of Eastern Europe; 2 in other words, 75% of the world's population resides in regions endemic for HBV. Of note, 70% percent of HBV carriers live in Asia, where perinatal transmission and horizontal infection are major contributors to the incidence of infection.
In Japan, a selective vaccination program intended to prevent perinatal HBV infection was initially implemented nationwide in 1986. This program, which receives financial support from the Japanese government, involves HBsAg testing of all pregnant women and inoculation of antiHBsAg human immunoglobulin (HBIG) and HBV (HB) vaccines to all infants born to HBsAg-positive mothers.
The present survey-based study aimed to estimate the prevalence of HBsAg among pregnant women in Hiroshima, Japan according to their birth year and to compare the prevalence rates of women born before and after 1986.
METHODS

P
REGNANT WOMEN WHO gave birth at one of 58 delivery hospitals/clinics in Hiroshima prefecture between 1 April 2010 and 31 March 2011 were eligible for this study. From each institution, we collected a list of information from medical records that was posted in a non-consolidated, anonymous format and included age (birth year of the pregnant women) and HBsAg and hepatitis C virus antibody (anti-HCV) test results and methods. We calculated the prevalence rates of HBsAg and anti-HCV and corresponding 95% confidence intervals (CI) among pregnant women after stratification into 5-year birth cohorts.
The prevalence of HBsAg and anti-HCV among pregnant women was compared with all the first-time blood donor women in the Chugoku area (2001) (2002) (2003) (2004) (2005) (2006) 3 in each age group. Trend of age for prevalence of HBsAg or anti-HCV was also analyzed (Cochran-Armitage trend test). Statistical analyses were undertaken with JMP version 11 (SAS Institute, Cary, NC, USA) This study was approved by the ethics committee of Hiroshima University (EKI-No. 395-1) as an epidemiological survey with non-consolidated, anonymous data (personal information was not included).
RESULTS
W
E RECEIVED NON-CONSOLIDATED, anonymous data from 41 obstetric and gynecologic hospitals/clinics with delivery facilities from among all 58 eligible hospitals/clinics in Hiroshima prefecture (Fig. 1) (Fig. 2) .
Hepatitis B surface antigen measurement methods, which differed among the institutions, included chemiluminescent enzyme immunoassay (CLEIA), chemiluminescence immunoassay (CLIA), magnetic agglutination test (MAT), enzyme immunoassay (EIA), and agglutination (particle agglutination [PA] and reversed passive hemagglutination assay). Reported anti-HCV testing methods included CLEIA, CLIA, PA, MAT, EIA, and latex agglutination using latex photometric immunoassay; however, 90% of the tests involved CLEIA and CLIA.
Among 15 233 pregnant women, only 78 women were identified as HBsAg positive. Although the overall prevalence of HBsAg was 0.51% (95% CI, 0.40-0.63%), the prevalence among the 1941 pregnant women born after 1986 was extremely low (0.10%; 95% CI, 0.0-0.25%), with only two positive cases (Fig. 3a , Table 1 ). Similarly, among 15 035 pregnant women tested for anti-HCV, 38 positive cases were found, and the overall anti-HCV prevalence was very low (0.25%; 95% CI, 0.17-0.33%) (Fig. 3b , Table 1 ). Notably, 2 (0.13%) pregnant women with ages of 32 and 43 years were found to have HBV and HCV coinfection. Compared with all the first-time blood donor women in the Chugoku area, the prevalence of HBsAg was similar in subjects younger than 34 years. A significant trend of age for the prevalence of HBsAg was observed both among pregnant women and first-time blood donor women (trend P < 0.0001 for both; Cochran-Armitage trend test). The prevalence of anti-HCV among pregnant women was similar to that among first-time blood donor women in each age group. However, unlike the first-time blood donor cohort, there was not a significant trend of age for the prevalence of anti-HCV among the pregnant women (trend P = 0.5177, Cochran-Armitage trend test) (Fig. 3) .
DISCUSSION
A CCORDING TO A report from the World Health Organization (WHO), the estimated prevalence of HBsAg in Japan was 2-4% 4 in 2005. Perinatal HBV infection, which results in a persistent carrier state, occurs in approximately 90% of babies born to mothers who are seropositive for HBsAg and HBV envelope antigen (HBeAg). 5, 6 In countries with a pediatric HBsAg prevalence of <1.0%, perinatal HBV infection is assumed to be the major route of transmission; accordingly, a rational approach to HBV infection control would include selective vaccination with HBIG and the HB vaccine as a combined passive-active immunoprophylaxis of babies born to HBsAg-and HBeAg-positive mothers. In contrast, perinatal transmission accounts for only 10-20% of persistent HBV infections in infants in countries where the prevalence of HBsAg exceeds 8%. 7, 8 In these hyperendemic countries, horizontal infection, rather than perinatal transmission, is the major route of infection among children younger than 5 years; accordingly, universal vaccination of newborn infants constitutes a rational method of infection control.
According to estimations of the number of HBV carriers and the frequencies of horizontal and perinatal HBV transmission from 1950 to 1985 in Japan, as reported by Sato et al., 9 the number of HBV carriers has decreased since the 1950s; furthermore, the estimated frequencies In Japan, the national health insurance system 10 provides all citizens with universal access to low-cost medical treatment; in addition, pregnant women are entitled to receive free pregnancy health checkups and a Maternal and Child Health handbook following registration at a local municipal office. In the context of this well-established social security system, the Japanese government initiated the above-described selective vaccination program to minimize perinatal HBV transmission among babies born to mothers identified as HBV carriers. This nationwide, government-funded program includes HBsAg testing of all pregnant women and the administration of HBIG and three rounds of HB vaccination to infants born to HBsAg-positive mothers.
In a 2003 study of school children, Koyama et al.
11
reported the efficacy of a combination of selective vaccination (HB vaccine) and passive immunoprophylaxis (HBIG) when given to babies born to mothers with HBsAg and HBeAg. To our knowledge, however, no previous serological survey has clarified the differences in HBV infection prevalence rates between adults born before and after 1986. Accordingly, we attempted to address this gap in our study and observed a reduction in the prevalence of HBsAg among pregnant women born after 1986. This finding suggests that the selective vaccination program implemented in 1986 has nearly eliminated the incidence of perinatal HBV infection. We further note that, among first-time blood donors at Japanese Red Cross blood centers between 2001 and 2006, the prevalence rates of HBsAg and anti-HCV were 0.31% and 0.26%, respectively (the nationwide value), and 0.46% and 0.28%, respectively (the Chugoku region-specific value).
3
The first-time blood donors were thought to be a healthy population who had never donated blood before and perhaps never undergone a hepatitis screening test. As shown in Figure 3 , the prevalence rates of HBsAg and anti-HCV in this study and that in the cohort of first-time blood donor women in the Chugoku area did not differ, except for the prevalence of HBsAg in the age group 35-44 years, suggesting that the subjects of our study were representative of a healthy general population, rather than merely a group at high risk of HBV or HCV infection. However, it has to be pointed out that the first-time blood donors were biased toward a more low-risk population because those who recognize any symptoms tend to avoid blood donation; moreover, all blood donors were screened by the questionnaire before donation. In this study, the prevalence of HBsAg in 35 years of age and older pregnant women was higher than that in the first-time blood donor women, and a significant trend of age for the prevalence of anti-HCV was not observed among the pregnant women unlike the first-time blood donor cohort. The reasons for these discrepancies may include issues of sample size; the number of the first-time blood donor cohort was 3-16 times larger than that of pregnant women in each age group. In this study, there were 2 (0.13%) pregnant women with HBV and HCV co-infection. However, medical history, family history, history of life, or genotype information were not available in this study, so we could not discuss the route of infection in these cases.
The WHO promotes universal vaccination, and recommends that all babies receive HB vaccines immediately after birth (i.e., within 24 h). Almost all WHO members (184 of 194 countries), 12 have adopted universal vaccination and have integrated HB vaccines into routine immunization programs, whereas other countries, such as Japan, have only adopted selective vaccination. However, the latter is not an effective preventive measure in countries where not all pregnant women are followed up by medical institutions before delivery. Accordingly, national vaccination program policies depend on nation-specific factors. In Japan, the selective vaccination program has been effective because of the established medical environment, 10 supportive economic conditions, and efforts of medical workers, all of which have led to the near abrogation of vertical HBV transmission. However, some studies note that horizontal HBV infection of infants has not been completely eradicated, 9, 13 and since 2000, new HBV genotype A infections have been spreading among adults, particularly in urban areas. 14 Compared with other Asian countries, Japan has a relatively lower HBsAg prevalence. In particular, HBsAgpositive rates are reported to be 0.5% or lower among young and middle-aged adults. 3, 15, 16 Currently, however, new preventive measures against HBV infection are needed as a result of the increased globalization of Asian countries. In consideration of these societal changes, and with the intent to prevent horizontal HBV infection, a universal vaccination program of all newborns was implemented in Japan on 1 October 2016. Because hepatitis B can be prevented with vaccination, these political measures are expected to have successful outcomes in the future.
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